SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Frederick Law Olmsted — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrederick Law Olmsted
Date of birth1822-04-26
IdentifiersMRN HR-NI022-SYN-TD; SSN (made up) 000-22-5519
Document date1895-10-27
AuthorNathan Calder, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month dementia review. [S]

History of Present Illness

Mr. Olmsted returns with his caregiver about six months after his first visit, twelve weeks after donepezil was increased to 10 mg each morning. He has had no nausea, diarrhea, dizziness, fainting, or vivid dreams, and his appetite is good. His memory is unchanged by his caregiver's account, and he enjoys the adult day program two days a week for its gardens. He has had no falls, no wandering, and no night-time confusion. His caregiver finished the education program, sleeps better, and has two free days a week. They went through the home safety checklist together this month: knob covers on the stove, locked medicines, and night lights on the way to the bathroom. [S]

ElementDetail
MedicineDonepezil 10 mg for twelve weeks; no side effects
CourseMemory unchanged; no new behavioral symptoms
SafetyNo falls or wandering; home safety checklist completed
CaregiverEducation program completed; adult day program two days a week

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo nausea, diarrhea, or loss of appetite
CardiovascularNegativeNo fainting or lightheadedness
NeurologicalPositiveMemory loss unchanged; no falls
PsychiatricNegativeMood fair to good; no hallucinations or agitation; PHQ-9 score 4

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Donepezil 5 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning with breakfastOral route1895-06-02 to 1895-08-04completedS
Donepezil 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning with breakfastOral route1895-08-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1895-10-27Body height175cmS
1895-10-27Body weight71kgS
1895-10-27Body mass index (BMI) [Ratio]23.2kg/m2S
1895-10-27Systolic blood pressure130mm[Hg]S
1895-10-27Diastolic blood pressure76mm[Hg]S
1895-10-27Heart rate60/minS
1895-10-27Respiratory rate14/minS
1895-10-27Body temperature36.6CelS
1895-10-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1895-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1895-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, pleasant, and engaged
CardiovascularRegular rhythm at 60 per minute; blood pressure 130/76 mmHg; weight 71.0 kg, stable since the wellness visit
NeurologicalOriented to person and place, not to date; no new focal signs; normal gait

Problems

ProblemClinical statusVerificationCodeProvenance
Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1activeconfirmed F03.A0S — Synthetic modern coding of his documented failing memory; the cause is unknown, so the type is left unspecified. Stage and scores are synthetic.
Common cold, with two nights of increased confusion after an over-the-counter nighttime cold medicine containing diphenhydramine; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.
Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairmentresolvedconfirmed R41.3S — Synthetic presenting concern at the index visit, superseded by the dementia diagnosis at the four-week visit; the failing memory is documented (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyMedication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics)Every visitCompleted todayNo anticholinergic, sedating, or other Beers-list drugs
SurveyNeuropsychiatric symptom screen (NPI-Q)Every visitCompleted todayMild apathy only; no hallucinations, agitation, wandering, or sleep disturbance
Medication safetyCholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreamsEach follow-up on treatmentCompleted todayOn 10 mg for twelve weeks: heart rate 60, no fainting, no gastrointestinal effects, weight stable at 71.0 kg, no vivid dreams; stable course
Medication safetyAntipsychotic appropriateness and taper reviewEvery visit if on an antipsychoticNot indicatedNot on an antipsychotic
ExaminationVascular risk-factor control (blood pressure, lipids, glucose, smoking)Every visitCompleted todayBlood pressure 130/76 mmHg; LDL 118 mg/dL and statin decision at the wellness visit; never smoked
ExaminationHome safety evaluationAt diagnosis and each follow-upCompleted todayChecklist reviewed: stove knob covers, locked medicines, night lights; the review missed at three months is now done
SurveyCognitive test (MoCA)Annually; every visit if a change is reportedUp to dateMoCA 19 six months ago; no change reported; due at the yearly review
SurveyADL (Katz) and IADL (Lawton-Brody)Annually, and at any reported changeUp to dateNo change reported; due at the yearly review
SurveyDementia stage (CDR or FAST)AnnuallyUp to dateCDR 1; due at the yearly review
SurveyDepression screen (PHQ-9)Annually, and at any reported changeCompleted todayPHQ-9 4, down from 6; no thoughts of self-harm
ExaminationFall-risk assessment (Timed Up and Go, gait and balance)AnnuallyUp to dateTimed Up and Go 11 seconds six weeks ago; no falls
ExaminationDriving safety (CDR-based)At diagnosis and annuallyUp to dateNot driving
Self-managementFirearms, wandering, and financial safetyAt diagnosis and with any changeCompleted todayNo firearms; bracelet worn; no wandering; finances overseen
SurveyCaregiver burden (Zarit Burden Interview) and caregiver needsAt diagnosis, then every 6 to 12 monthsUp to dateZarit 24 three months ago; caregiver sleeping better with two free days a week; repeat at the yearly review
Self-managementAdvance care planning and goals of careAt diagnosis, then annually and at stage changesUp to dateRecorded three months ago and reviewed at the wellness visit
LaboratoryTSH, vitamin B12, blood count, and metabolic panelAt diagnosis; repeat only with acute cognitive worseningUp to dateNormal at diagnosis; no acute change
LaboratorySyphilis and HIV testingOnly with risk factors or atypical featuresNot indicatedNo risk factors
ImagingStructural brain MRI, non-contrastOnce at diagnosis; repeat only with an atypical course or focal changeUp to dateDone once at diagnosis
LaboratoryAmyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotypeBefore anti-amyloid therapy, or when the result would change careNot indicatedDeclined; no change in his wishes
ImagingAnti-amyloid antibody therapy with ARIA surveillance MRIOnly if anti-amyloid therapy is startedNot indicatedNot chosen
Self-managementLifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagementOngoingCompleted todayDaily walks and the adult day program; hearing normal at the wellness visit; eye examination still to be booked
ReferralDementia care navigation and caregiver support programAt enrollment, with ongoing supportCompleted todayEducation program completed; adult day program two days a week
Self-managementVaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap)Yearly, per the CDC scheduleUp to dateInfluenza, PCV20, and zoster dose 1 at the wellness visit; zoster dose 2 and Tdap due in the next four months

Goal progress:

Guideline basis: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026)

Follow-up: Dementia review in about three months; yearly review with MoCA, ADL and IADL, CDR stage, and the Zarit Burden Interview at one year from diagnosis. Second zoster dose and Tdap within the next four months. [S]